Press Releases

 
Press Releases
  Date Title and Summary View
Oct 9, 2002
PITTSBURGH, Oct 9, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) today announced that it has named Patrick J. Gallagher as Vice President, Business Development. Mr. Gallagher will focus his attention on identifying company and/or product acquisitions, partnerships, licensing activities and other strategic opportunities. ...
Sep 16, 2002
PITTSBURGH, Sep 16, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of four cents per share will be paid on October 15, 2002, to shareholders of record September 30, 2002. CONTACT: Mylan Laboratories Inc., Pittsburgh Patricia Sun
Jul 25, 2002
PITTSBURGH, Jul 25, 2002 (BUSINESS WIRE) -- Financial Highlights -- Net revenues increased 16% to $275.5 million. -- Gross profit increased 21% to $147.6 million. -- Net earnings increased 22% to $61.8 million. -- Earnings per diluted share increased 22% to $.49 per share.
Jul 24, 2002
PITTSBURGH, Jul 24, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that Gary E. Sphar was named Vice President-Corporate Controller. Mr. Sphar will be responsible for accounting policies and functions, internal and external financial reporting, budgeting, forecasting and financial systems. Mr. Sphar joined Myl...
Jul 18, 2002
PITTSBURGH, Jul 18, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) today announced that effective September 1, 2002, Robert J. Coury, 41, will become Chief Executive Officer of Mylan Laboratories and Louis J. DeBone, 56, will become President and Chief Operating Officer. Mylan's Chairman of the Board and current Chief Executive...
Jul 17, 2002
PITTSBURGH, Jul 17, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that it will release its first quarter fiscal 2003 financial results before the market opens on Thursday, July 25, 2002. Mylan management will host a conference call and live Webcast at 10:00 AM EDT to discuss the financial results and relevant c...
Jul 9, 2002
PITTSBURGH, Jul 9, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Nizatidine Capsules, 150 mg and 300 mg. Mylan Nizatidine is the generic equivalent of Reliant Pharmaceuticals' Axid...
Jul 2, 2002
PITTSBURGH, Jul 2, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Applications (ANDAs) for Lisinopril Tablets in 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg strengths and Lisinopril and Hydrochlorothiazide Tablets in 10 mg/12.5 m...
Jun 21, 2002
PITTSBURGH, Jun 21, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Tablets, 50 mg. Mylan's Tramadol product is the generic version of R.W. Johnson Pharmaceutical Research Institute's Ul...
Jun 17, 2002
PITTSBURGH--(BUSINESS WIRE)--June 17, 2002--Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of four cents per share will be paid on July 15, 2002 to shareholders of record June 30, 2002. --30--ad/ny* CONTACT: Mylan Laboratories Inc., Pittsbur...
Page: FirstPrevious ...
109
NextLast
= add release to Briefcase